The SmPC classifies nausea and diarrhoea as 'very common' (affecting more than 1 in 10 patients), while abdominal pain, abdominal distension, vomiting, flatulence and dyspepsia are classified as 'common' (affecting between 1 in 10 and 1 in 100 patients)
Clinical trials have demonstrated significant weight loss and glycaemic control with tirzepatide, with the SURMOUNT and SURPASS trial programmes providing robust evidence for its efficacy
The stomach, thigh, and upper arm are the best places to inject Wegovy because of the fat layer for fast absorption
Free radicals can damage cells and DNA if left unchecked, resulting in issues such as: Increased signs of aging (such as wrinkled or dry skin) Headaches Low energy levels Increased risk of illness Lack of mental clarity Joint pain Fatigue Antioxidants, such as glutathione, rid the body of free radicals before they can do too much harm